Literature DB >> 11448456

Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.

S M Bailey1, A D Lewis, L H Patterson, G R Fisher, R J Knox, P Workman.   

Abstract

Evidence suggests that DT-diaphorase is involved in the activation and mechanism of cytotoxicity of the investigational indoloquinone anticancer drug EO9 under aerobic conditions. Data also implicate a role for other enzymes including NADPH: cytochrome P450 reductase, especially in low DT-diaphorase tumour cells and under hypoxic conditions. Here, we used purified rat NADPH: cytochrome P450 reductase to provide additional evidence in support of a role for this enzyme in activation of EO9 to generate free radical and DNA-damaging species. Electron spin resonance spectrometry studies showed that NADPH: cytochrome P450 reductase reduced EO9 to a free radical species, including a drug radical (most likely the semiquinone) and reactive oxygen species. Plasmid DNA experiments showed that reduction of EO9 catalysed by NADPH: cytochrome P450 reductase results in single-strand breaks in DNA. The information obtained may contribute to the understanding of the molecular mechanism of DNA damage and cytotoxicity exerted by EO9 and may be useful in the design of future bioreductive drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448456     DOI: 10.1016/s0006-2952(01)00674-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Influence of bulk and tapped density on the determination of the thermal conductivity of powders and blends.

Authors:  Kendra Schröder; Katja Schmid; Raimar Löbenberg
Journal:  AAPS PharmSciTech       Date:  2007-09-28       Impact factor: 3.246

Review 2.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 3.  Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn off-on Probes for Hypoxia Imaging.

Authors:  Ewelina Janczy-Cempa; Olga Mazuryk; Agnieszka Kania; Małgorzata Brindell
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

4.  Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.

Authors:  Ayelet M Samuni; William DeGraff; Murali C Krishna; James B Mitchell
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

5.  Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.

Authors:  Jiechuang Su; Yongchuan Gu; Frederik B Pruijn; Jeff B Smaill; Adam V Patterson; Christopher P Guise; William R Wilson
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

6.  The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.

Authors:  D Kostrzewa-Nowak; M J I Paine; C R Wolf; J Tarasiuk
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

7.  Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.

Authors:  Linda Spiegelberg; Ruud Houben; Raymon Niemans; Dirk de Ruysscher; Ala Yaromina; Jan Theys; Christopher P Guise; Jeffrey B Smaill; Adam V Patterson; Philippe Lambin; Ludwig J Dubois
Journal:  Clin Transl Radiat Oncol       Date:  2019-01-18

8.  Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering.

Authors:  Jacqueline Ellis; Aldo Gutierrez; Igor L Barsukov; Wei-Cheng Huang; J Günter Grossmann; Gordon C K Roberts
Journal:  J Biol Chem       Date:  2009-10-26       Impact factor: 5.157

Review 9.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.